Antiviral agents: Nonantiviral drugs

Journal of the American Academy of Dermatology

Volumn 47, Issue 4, 2002, Pages 581-599

  Brown, Tricia J ^a   McCrary, Monica ^a   Tyring, Stephen K ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHAN3 INTERFERON; AMANTADINE; AMPHOTERICIN B; ANTIVIRUS AGENT; BEHENYL ALCOHOL; CIDOFOVIR; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; IMIQUIMOD; LAMIVUDINE; OSELTAMIVIR; PEGINTERFERON ALPHA2B; PENCICLOVIR; PREDNISOLONE; PROBENECID; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RESIQUIMOD; RIBAVIRIN; RIMANTADINE; TRIFLURIDINE; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIDARABINE; ZANAMIVIR; ZIDOVUDINE;

ANEMIA; ASTHMA; AUTOIMMUNE DISEASE; BIRTH DEFECT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG SCREENING; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYE TOXICITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENITAL HERPES; GRANULOCYTOPENIA; HEADACHE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; INJECTION PAIN; INTRAOCULAR HYPERTENSION; KIDNEY FAILURE; LETHARGY; LICHEN PLANUS; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHLEBITIS; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; REVIEW; SKIN MANIFESTATION; SKIN ULCER; SPONTANEOUS ABORTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UVEITIS; VARICELLA ZOSTER VIRUS; VERTIGO; VIRAL SKIN DISEASE; VIRUS HEPATITIS; VOMITING; WART VIRUS; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

EID: 0036787030     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.121033     Document Type: Article

References (217)

1. Wagstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:153-205.
2. Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem 1978;253:8721-7.
3. Littler E, Zeuthen J, McBride AA, Trost Sorensen E, Powell KL, Walsh-Arrand JE, et al. Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J 1986;5:1959-66.
4. Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980;255:7204-7.
5. Elion GB, Furman PH, Fyfe JA, De Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A 1977; 74:5716-20.
6. Spruance SL, Steward JC, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990;161:185-90.
7. Fiddian AP, Brigden D, Yeo JM, Hickmott EA. Acyclovir: an update on the clinical applications of this antiherpes agent. Antiviral Res 1984;4:99-117.
8. Goldberg LH, Kaufman R, Kurtz TO, Conant MA, Eron LJ, Batenhorst RL, et al. Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. The Acyclovir Study Group. Arch Dermatol 1993;129:582-7.
9. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
10. Whitley RJ, Levin M, Barton N, Hershey BJ, Davis G, Keeney RE, et al. Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J Infect Dis 1984;150:323-9.
11. Spruance SL, Crumpacker CS, Schnipper LE, Kern ER, Marlowe S, Arndt KA, et al. Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir. Antimicrob Agents Chemother 1984;25:553-5.
12. Raborn GW, McGaw WT, Grace M, Houle L. Herpes labialis treatment with acyclovir 5 per cent ointment. Can Dent Assoc J 1989;55:135-7.
13. Fiddian AP, Ivanyi L. Topical acyclovir in the management of recurrent herpes labialis. Br J Dermatol 1983;109:321-6.
14. Spruance SL, Schnipper LE, Overall JC Jr, Kern ER, Wester B, Modlin J, et al. Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol. J Infect Dis 1982;146:85-90.
15. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC III. Treatment of adult varicella with oral acyclovir: a randomized, placebo-controlled trial. Ann Intern Med 1992;117:358-63.
16. Balfour HH Jr, Kelly JM, Suarez CS, Heussner RC, Englund JA, Crane DD, et al. Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 1990;116:633-9.
17. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991;325:1539-44.
18. Nyerges G, Meszner Z, Gyarmati E, Kerpel-Fronius S. Acyclovir prevents dissemination of varicella in immunocompromised children. J Infect Dis 1988;157:309-13.
19. Meszner Z, Nyerges G, Bell AR. Oral acyclovir to prevent dissemination of varicella in immunocompromised children. J Infect 1993;26:9-15.
20. American Academy of Pediatrics Committee on Infectious Diseases. The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics 1993;91:674-6.
21. Bean B, Braun C, Balfour HH Jr. Acyclovir therapy for acute herpes zoster. Lancet 1982;2:118-21.
22. Peterslund NA, Seyer-Hansen K, Ipsen J, Esmann V, Schonheyder H, Juhl H. Acyclovir in herpes zoster. Lancet 1981;2:827-30.
23. McGill J, MacDonald DR, Fall C, McKendrick GDW, Copplestone A. Intravenous acyclovir in acute herpes zoster infection. J Infect Dis 1983;6:157-61.
24. Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988;85(Suppl 2A):79-83.
25. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989;102:93-5.
26. Huff JC, Bean B, Balfour HH Jr, Laskin OL, Connor JD, Corey L, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988; 85(Suppl 2A):84-9.
27. Huff JC, Drucker JL, Clemmer A, Laskin OL, Connor JD, Bryson YL, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a re-analysis. J Med Virol 1993;Suppl 1:93-6.
28. van den Broek PJ, van der Meer JW, Mulder JD, Versteeg J, Mattie H. Limited value to acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study. Infection 1984;12:338-41.
29. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997;157:909-12.
30. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330:896-900.
31. Whitley RF, Weiss H, Gnann JW Jr, Tyring S, Mertz GJ, Pappas PG, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996;125: 376-83.
32. Cohen JI, Brunell PA, Staus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999;130:922-33.
33. Lau RJ, Emery MG, Galinsky RE. Unexpected accumulation of acyclovir in breast milk with estimation of infant exposure. Obstet Gynecol 1987;69:468-71.
34. Meyer LJ, De Miranda P, Sheth N, Spruance S. Acyclovir in human breast milk. Am J Obstet Gynecol 1988;158:586-8.
35. Taddio A, Klein J, Koren G. Acyclovir excretion in human breast milk. Ann Pharmacother 1994;28:585-7.
36. Collins P, Ellis NM. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol 1993;Suppl 1:58-66.
37. Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989;320:293-6.
38. Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterisation of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1991;35:2322-8.
39. Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind test. Ann Intern Med 1982;96:265-9.
40. Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH Jr. Herpes simplex resistance to acyclovir: a study in a tertiary care centre. Ann Intern Med 1990;112:416-22.
41. Reusser P. Virostatika-Resistenz bei Herpesviren: Mechanisen, Haulgkeit und klinische Bedeutung. Schweiz Med Wochenschr 1994;124:152-8.
42. Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998;42:868-72.
43. Patel R, Barton SE. Antiviral chemotherapy in genital herpes simplex virus infections. Int J STD AIDS 1995;6:320-8.
44. McGrath BJ, Newman CL. Genital herpes simplex infections in patients with the acquired immunodeficiency syndrome. Pharmacotherapy 1994;14:529-42.
45. Easterbrook P, Wood MJ. Successors to acyclovir. J Antimicrob Chemother 1994;34:307-11.
46. Snoeck R, Gerard M, Sadzot-Delvaux C, Andrei G, Balzarini J, Reymen D, et al. Meningoradiculoneuritis due to acyclovir-resistant varicella-zoster virus in an acquired immune deficiency syndrome patient. J Med Virol 1994;42:338-47.
47. Pahwa S, Biron K, Lira W, Swenson P, Kaplan MH, Sadick N, et al. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 1988;260:2879-82.
48. Linnemann CC Jr, Biron KK, Hoppenjans WG, Solinger AM. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS 1990;4:577-9.
49. Jacobson MA, Berger TG, Fikrig S, Becherer P, Moohr JW, Stanat SC, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:187-91.
50. Smith KJ, Kahlter C, Davis DC, James WD, Skelton HG, Angritt P. Acyclovir-resistant varicella zoster responsive to foscarnet. Arch Dermatol 1991;127:1069-71.
51. Pottage JC, Kessler HA. Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis 1995;4:115-24.
52. Cooper DA, Pehrson PO, Pedersen C, Moroni M, Oksenhendler E, Rozenbaum W, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind, randomized trial. AIDS 1993;7:197-207.
53. Youle MS, Gazzard BG, Johnson MA, Cooper DA, Hoy JF, Busch H, et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 1994;8:641-9.
54. 3. The Terry Beirn Community Programs for Clinical research on AIDS (CPCRA). Clin Infect Dis 1998;26:85-90.
55. Erbelding EJ, Chaisson RE, Gallant JE, Moore RD. Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease. Antivir Ther 1997;2:71-7.
56. Soul-Lawton J, Seaber E, On N, Wooton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;39:2759-64.
57. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53.
58. Fife KH, Barbarash RA, Rudolph T, Degregario B, Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis 1997; 24:481-6.
59. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002;34:958-62.
60. Reitano M, Tyring SK, Lang W, Thoming C, Worm AM, Borelli S, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 1998;178:603-10.
61. Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser resurfacing. Dermatol Surg 1999; 25:242-6.
62. Nanni CA, Alster TS. Herpes simplex virus prophylaxis for cutaneous laser resurfacing: a comparison of acyclovir, valacyclovir and famciclovir. Laser Surg Med 1998;Suppl 10:66.
63. Lowance D, Neumayer HH, Legendre CM, Squiffiet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462-70.
64. Bell WR, Chulay JD, Reinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997;76:369-80.
65. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ, and the International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002;13:12-21.
66. Boyd MR, Safrin S, Kern ER. Penciclovir: a review of the spectrum of activity, selectivity, and cross resistance pattern. Antivir Chem Chemother 1993;4(Suppl 1):3-11.
67. Lazarus HM, Belanger R, Candoni A, Aoun M, Jurewicz R, Marks L. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group. Antimicrob Agents Chemother 1999; 43:1192-7.
68. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36:2747-57.
69. Vere Hodge RA. Famciclovir and penciclovir: the mode of action of famciclovir including into conversion to penciclovir. Antivir Chem Chemother 1993;4:67-84.
70. Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. The Topical Penciclovir Collaborative Study Group. JAMA 1997;277:1374-9.
71. Spruance SL, Rowe NH, Robom GW,Thibodeau EA, D'Ambrosio JA, Bemstein DI. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: a double-blind, dose-ranging placebo-controlled, multicenter trial. J Infect Dis 1999;179:303-10.
72. Sacks SL, Aoki F, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996;276:44-9.
73. Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA 1998;280:887-92.
74. Frechette G, Romanawski B, on behalf of the Famciclovir Study Group. Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients. Presented at the Sixth Annual Canadian Conference on HIV/AIDS Research; 1997 May 22-25; Ottawa, Ontario, Canada. Oral presentation 301.
75. Schacker T, Hu HL, Koelle DM, Zeh J, Saltzman R, Boon R, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998;128:21-8.
76. Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Famciclovir Herpes Zoster Clinical Study Group. Int J Antimicrob Agents 1994;4:241-6.
77. Tyring SK, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995;123:89-96.
78. Huse DM, Schainbaum S, Kirsch AJ, Tyring S. Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. Am J Health Syst Pharm 1997;54:1180-4.
79. Tyring S, Engst R, Corriveau C, Robillard N, Trottier S, Van Slycken S, et al. Famciclovir for ophthalmic zoster: a randomized acyclovir controlled study. Br J Ophthalmol 2001;85:576-81.
80. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks J. Antiviral therapy for herpes zoster. Arch Fam Med 2000;9:863-9.
81. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001; 19:13-22.
82. Loveless M, Sacks SL, Harris JR. Famciclovir in the management of first-episode genital herpes. Infect Dis Clin Prac 1997; 6(Suppl 1):S12-6.
83. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther 1989;40:213-85.
84. Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990; 161:1078-84.
85. Balfour HH Jr. Antiviral drugs. N Engl J Med 1999;340:1255-68.
86. Devianne-Garrigue I, Pellegrin I, Denisi R, Dupon M, Ragnaud JM, Barbeau P, et al. Foscarnet decreases HIV-1 plasma load. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:46-50.
87. Lokke Jensen B, Weismann K, Mathiesen L, Klem Thomsen H. Atypical varicella-zoster infection in AIDS. Acta Derm Venereol 1993;73:123-5.
88. Paar DP, Straus SE. Treatment of acyclovir (ACV)-resistant zoster with foscarnet in a man with AIDS [abstract]. Antivir Res 1991;15(Suppl 1):153.
89. Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, Mills J, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991; 115:19-21.
90. Javaly K, Wohlfeiler M, Kalayjian R, Klein T, Bryson Y, Grafford K. Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. J Acquire Immune Defic Syndr 1999; 21:301-6.
91. Safrin S, Kemmerly S, Plotkin B, Smith T, Weissbach N, De Veranez D, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994;169:193-6.
92. Birch CJ, Tyssen DP, Tachedjian G, Doherty R, Hayes K, Mijch A, et al. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infection. J Infect Dis 1992;166:108-12.
93. Pelosi E, Hicks KA, Sacks SL, Coen DM. Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet. Adv Exp Med Biol 1992;312:151-8.
94. Spector SA, Tyndall M, Kelley E. Inhibition of human cytomegalovirus by trifluorothymidine. Antimicrob Agents Chemother 1983;23:113-8.
95. Kessler HA, Hurwitz S, Farthing C, Benson CA, Feinberg J, Kuritzkes DR, et al. Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). Aids Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12: 147-52.
96. Lalezari J, Schacker T, Feinberg J, Gathe J, Lee S, Cheung T, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997;176:892-8.
97. Snoeck R, Andrei G, Gerard M, Silverman A, Hedderman A, Balzarini J, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC). Clin Infect Dis 1994;18:570-8.
98. Sacks S, Shafran S, Francisco D. A randomized, double-blind, placebo controlled pilot study of cidofovir topical gel for recurrent genital herpes infection. Abstract presented at the American Academy of Dermatology 55th Annual Meeting; 1997 Mar 21-26; San Francisco. Poster 290.
99. Sacks SL, Shafran SD, Diaz-Mitoma F, Trottier S, Sibbald RG, Hughes A, et al. A multicenter phase I/II dose escalation study of single-dose cidofavir gel for treatment of recurrent genital herpes. Antimicrob Agents Chemother 1998;42:2996-9.
100. Zabawski EJ Jr, Cockerell CJ. Topical and intralesional cidofovir: A review of pharmacology and therapeutic effects. J Am Acad Dermatol 1998;39:741-5.
101. Lateef F, Don PC, Kaufmann M, White SM, Weinberg JM. Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. Arch Dermatol 1998;134:1169-70.
102. Wagner TL, Horton VL, Carlson GL, Myhre PE, Gibson SJ, Imbertson LM, et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 1997;9:837-45.
103. Tomai MA, Gibson SJ, Imbertson LM, Miller RL, Myhre PE, Reiter MJ, et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 1995;28:253-64.
104. Spruance SL, Tyring SK, Smith MH, Meng T-C. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 2001;184:196-200.
105. Hamzeh FM, Lietman PS. Intranuclear accumulation of subgenomic noninfectious human cytomegalovirus DNA in infected cells in the presence of ganciclovir. Antimicrob Agents Chemother 1991;35:1818-23.
106. Biron KK, Stanat SC, Sorrell JB, Fyfe JA, Keller PM, Lambe CU, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1(hydroxymethyl)ethoxy] methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 1985;82:2473-7.
107. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells [published errata appear in Nature 1992;359:85 and Nature 1993;366:756]. Nature 1992;358:162-4.
108. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992;358:160-2.
109. Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995;17:425-32.
110. Erice A, Jordan MC, Chace BA, Fletcher C, Chinnook BJ, Balfour HH Jr. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987;257:3082-7.
111. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346:69-74.
112. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325:1601-7.
113. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscamet or ganciclovir for cytomegalovirus retinitis. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group [published erratum appears in N Engl J Med 1992;326: 1172]. N Engl J Med 1992;326:213-20.
114. Safrin S, Cherrington J, Jaffe HS. Clinical uses of cidofovir. Rev Med Virol 1997;7:145-6.
115. Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 1997;41:594-5.
116. Ho HT, Woods KL, Bronson JJ, DeBoeck H, Martin JC, Hitchcock MJ. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-phosphonylmethoxypropyl]cytosine. Mol Pharmacol 1992;41:197-202.
117. Lalezari JP, Kemper C, Stagg R. A randomized, controlled study of the safety and efficacy of intravenous cidofovir (CDV, HPMPC) for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS [abstract]. Presented at the XI International Conference on AIDS; 1996 July 7-12; Vancouver, British Columbia, Canada.
118. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann Intern Med 1997;126:264-74.
119. Kirsch LS, Arevalo JF, Chavez de la Paz E, Munguia D, De Clercq E, Freeman WR. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995;102:533-42.
120. Rahhal FM, Arevalo JF, Chavez de la Paz E, Munguia D, Azen SP, Freeman WR. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. Ann Intern Med 1996;125:98-103.
121. Marwick C. First "antisense" drug will treat CMV retinitis. JAMA 1998;280:871.
122. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11: 84-92.
123. McQuillan GM, Alter MJ, Moyer LA, Lambert SB, Margolis HS. A population based serologic study of hepatitis C infection in the United States. In: Rizzetto M, Purcell RH, Gerlin JL, Verme G, editors. Viral hepatitis and liver disease. Turin, Italy: Edizioni Minerva Medica; 1997. p. 267-70.
124. Parsons ME, Russo GG, Millikan LE. Dermatologic disorders associated with viral hepatitis infections. Int J Dermatol 1996;35:77-81.
125. Sarkany I. The skin-liver connection. Clin Exp Dermatol 1988; 13:151-9.
126. Daoud MS, Gibson LE, Daoud S, el-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc 1995;70:559-64.
127. Hadziyannis SJ. Nonhepatic manifestations and combined diseases in HCV infection. Dig Dis Sci 1996;41 (Suppl 12):63S-74S.
128. Gresser I. Biologic effects of interferons. J Invest Dermatol 1990;95(Suppl 6):66S-71S.
129. Woo MH, Burnakis TG. Interferon alfa in the treatment of chronic viral hepatitis B and C. Ann Pharmacother 1997;31:330-7.
130. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330:88-94.
131. Alexander GJ, Brahm J, Fagan EA, Smith HM, Daniels HM, Eddleston AL, et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987;2:66-9.
132. Hoofnagle JH, Peters MG, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. Randomized controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988;95:1318-25.
133. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301.
134. Lok ASF, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-7.
135. Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J, et al. A randomized controlled trial of recombinant alpha interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887-92.
136. Wong DK, Cheung AM, O'Rourke K. Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
137. Weiland O, Schvarz R, Wejstal R, Norkrans G, Fryden A. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. J Hepatol 1990;11:S57-S62.
138. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-7.
139. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU if interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
140. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
141. Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alpha-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-8.
142. Wills RJ, Dennis S, Spiegel HE, Gibson DM, Nadler PI. Interferon kinetics and adverse reaction after intravenous, intramuscular, and subcutaneous infection. Clin Pharmacol Ther 1984;35:722-7.
143. Bini EJ, Weinshel EH. Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C. Mayo Clin Proc 1999;74:367-70.
144. Brenard R. Practical management of patients treated with alpha interferon. Acta Gastroenterol Belg 1997;60:211-3.
145. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351:83-7.
146. Stoia J. Hepatitis C: new treatment options. AIDS Treat News 1998;302:5.
147. Davis GL, Esterban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
148. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci 1991; 88:8495-9.
149. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo controlled trial. Hepatology 1997;25:241-4.
150. Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
151. Dienstag JL, Schiff ER, Mitchell M, Casey DE Jr, Gitlin N, Lissoos T, et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1999;30:1082-7.
152. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113: 1258-63.
153. Singh N, Gayowski T, Wannstedt CF. Pretransplant famciclovir for prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997;63:1415-9.
154. Heathcote EJ, Jeffers L, Wright T. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. Presented at the 49th American Association for the Study of Liver Disease; 1998 Nov 6-10; Chicago. Abstract 620.
155. Edwards L, Ferenczy A, Eton L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papilloma Virus. Arch Dermatol 1998;134:25-30.
156. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38: 230-9.
157. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5.
158. Vance JC, Bart BJ, Hansen RC, Reichman RC, McEwen C, Hatch KD, et al. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986;122:272-7.
159. Eton LJ, Judson F, Tucker S, Prawer S, Mills J, Murphy K, et al. Interferon therapy for condyloma acuminata. N Engl J Med 1986;315:1059-64.
160. Freidman-Kien AE, Eton LJ, Conant M, Growdon W, Badiak H, Bradstreet PW, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA 1988;259:533-8.
161. Snoeck R, Van Ranst M, Andrei G, De Ciercq E, De Wit S, Poncin M, et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue [letter]. N Engl J Med 1995;333:943-4.
162. Douglas J, Carey T, Tyring S. A phase 1/11 study of cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection. Poster presented at the 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC. Poster No. 334.
163. Syed TA, Goswami J, Ahmadpour OA, Ahmad SA. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J Dermatol 1998;25:309-13.
164. Smith KJ, Liota E, Yager J, Menon P. Treatment of molluscum contagiosum with topical imiquimod [poster presentation] Presented at the 57th Annual Meeting of the American Academy of Dermatology; 1999 Mar 19-24; New Orleans. p. 352.
165. Meadows KP, Tyring SK, Pavia AT, Rallis TM. Resolution of recalcitrant molluscum contagiosum lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997;133:987-990.
166. Davies EG, Thrasher A, Lacey K, Harper J. Topical cidofovir for severe molluscum contagiosum [letter]. Lancet 1999;353:2042.
167. Nelson MR, Chard S, Barton SE. Intralesional interferon for the treatment of recalcitrant molluscum contagiosum in HIV antibody positive individuals-a preliminary report. Int J STD AIDS 1995;6:351-2.
168. Hourihane J, Hodges E, Smith J, Keefe M, Jones A, Connett G. Interferon alpha treatment of molluscum contagiosum in immunodeficiency. Arch Dis Child 1999;80:77-9.
169. Calista D, Boschini A, Landi G. Resolution of disseminated molluscum contagiosum with highly active antiretroviral therapy (HAART) in patients with AIDS. Eur J Dermatol 1999;9:211-3.
170. Cattelan AM, Sasset L, Corti L, Stiffan S, Meneghetti F, Cadrobbi P. A complete remission of recalcitrant molluscum contagiosum in an AIDS patient following highly active antiretroviral therapy (HAART) [letter]. J Infect 1999;38:58-60.
171. Horn CK, Scott GR, Benton EC. Resolution of severe molluscum contagiosum on effective antiretroviral therapy [letter]. Br J Dermatol 1998;138:715-7.
172. Hurni MA, Bohlen L, Furrer H, Braatner LR. Complete regression of giant molluscum contagiosum lesions in an HIV-infected patient following combined antiretroviral therapy with saquinavir, zidovudine, and lamivudine [letter]. AIDS 1997;11:1784-5.
173. Betlloch I, Pinazo I, Mestre F, Altes J, Villalonga C. Molluscum contagiosum in human immunodeficiency virus infection: response to zidovudine [letter]. Int J Dermatol 1989;28:351-2.
174. Karp JE, Groopman JE, Broder S. Cancer in AIDS. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott Co; 1993. p. 2093-110.
175. Sturzi M, Zietz C, Monini P, Ensoli B. Human herpesvirus-8 and sarcoma: relationship with the multistep concept of tumorigenesis. Adv Cancer Res 2001;81:125-59.
176. Duvic M, Friedman-Kien AE, Looney DJ, Miles SA, Myskowski PL, Scadden DT, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Arch Dermatol 2000;136:1461-9.
177. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
178. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. J Clin Invest 1997;99:2082-6.
179. Boulanger E. Human herpesvirus 8: pathogenic role and sensitivity to antiviral drugs. Ann Biol Clin (Paris) 1999;57:19-28.
180. Boivin G, Gaudreau A, Toma E, Lalonde R, Routy JP, Murray G, et al. Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy. Antimicrob Agents Chemother 1999;43:377-80.
181. Glesby MJ, Hoover DR, Weng S, Graham NM, Phair JP, Detels R, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996; 173:1477-80.
182. Mocroft A, Youle M, Gazzard B, MorcinekJ, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996;10:1101-5.
183. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 1999;340:1063-70.
184. Robles R, Lugo D, Gee L, Jacobson MA. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:34-8.
185. Morfeldt L, Torrsander J. Long-term remission of Kaposi's sarcoma following foscamet treatment in HIV-infected patients. Scand J Infect Dis 1994;26:749-52.
186. Humphrey RW, Davis DA, Newcomb FM, Yarchoan R. Human herpesvirus 8 (HHV-8) in the pathogenesis of Kaposi's sarcoma and other diseases. Leuk Lymphoma 1998;28:255-64.
187. Hammound Z, Parenti DM, Simon GL. Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment [letter]. Clin Infect Dis 1998;26:1233.
188. Badiaga S, Parola P, Zandotti C, Brouqui P. Successful treatment of Kaposi's sarcoma with a combination of antiviral drug therapy and chemotherapy: two case reports [letter]. Clin Infect Dis 1998;27:1558.
189. Simonart T, Noel JC, De Dobbeleer G, Parent D, Van Vooren JP, De Clercq E, et al. Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: report of a case. J Med Virol 1998;55:215-8.
190. Krown SE, Real FX, Cunningham-Rundles S, Myskowski PL, Koziner B, Fein S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983;308:1071-6.
191. Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 1988;2:1218-22.
192. De Wit R, Schattenkerk JKME, Boucher CAB, Bakker PJM, Veenhof KHN, Danner SA. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet 1988;2:1214-7.
193. Abrams DI, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol 1987;14(2 Suppl 2): 43-7.
194. Groopman JE, Gottlieb MS, Goodman J, Mitsuyasu RT, Conant MA, Prince H, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:671-6.
195. Morris AK, Valley AW. Overview of the management of AIDS-related Kaposi's sarcoma. Ann Pharmacother 1996;30:1150-63.
196. Krown SE. Interferon and other biologic agents for the treatment of Kaposi's sarcoma. Hematol Oncol Clin North Am 1991; 5:311-22.
197. Schooley RT, Dolin R. Epstein-Barr virus (infectious mononucleosis). In: Mandell GL, Douglas RJ Jr, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone; 1990. p. 1172-85.
198. Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-I-yl) guanine (BRL39123) in cell culture. Antimicrob Agents Chemother 1987;31:1238-42.
199. Bacon TH, Boyd MR. Activity of penciclovir against Epstein-Barr virus. Antimicrob Agents Chemother 1995;39:1599-602.
200. Straus SE. Epstein-Barr virus and human herpes virus type 6. In: Galasso GJ, Whitely RJ, Merigan TC, editors. Antiviral agents and viral diseases of man. 3rd ed. New York: Raven Press; 1990. p. 647-68.
201. Pagano JS, Sixbey JW, Lin JC. Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother 1983;12:113-21.
202. Andersson J, Britton S, Ernberg I, Andersson U, Henle W, Skoldenberg B, et al. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J Infect Dis 1986;153:283-90.
203. Andersson J, Skoldenberg B, Henle W, Giesecke J, Ortqvist A, Julander I, et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection 1987;15(Suppl 1):S14-20.
204. van der Horst C, Joncas J, Ahronheim G, Gustafson N, Stein G, Gurwith M, et al. Lack of effect on peroral acyclovir for the treatment of infectious mononucleosis. J Infect Dis 1991;164:788-92.
205. Andersson J, Ernberg I. Management of Epstein-Barr virus infections. Am J Med 1988;85:107-15.
206. Straus SE, moderator. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1992;118: 45-58.
207. Naher H, Helfrich S, Hartmann M, Freese UK. EBV-Replikation und Therapie der oralen Haarleukoplakie mit Acyclovir. Hautarzt 1990;41:680-2.
208. Glick M, Pliskin ME. Regression of oral hairy leukoplakia after oral administration of acyclovir. Gen Dent 1990;38:374-5.
209. Herbst JS, Morgan J, Raab-Traub N, Resnick L, Comparison of the efficacy of surgery and acyclovir therapy in oral hairy leukoplakia. J Am Acad Dermatol 1989;21:753-6.
210. Ochsendorf FR, Schofer H, Runne U, Milbradt R. Therapie der oralen Haarlenkoplakie mit Acyclovir. Hautarzt 1988;39:736-8.
211. Wray SK, Gilbert BE, Noall MW, Knight V. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 1985;5:29-37.
212. Flynn DL, Becker DP, Dilworth VM, Highkin MK, Hippenmeyer PJ, Houseman KA, et al. The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease. Drug Des Discov 1997;15:3-15.
213. Flynn DL, Abood NA, Holwerda BC. Recent advances in antiviral research: identification of inhibitors of the herpesvirus proteases. Curr Opin Chem Biol 1997;1:190-6.
214. Junker U, Baker J, Kalfoglou CS, Veres G, Kaneshima H, Bohnlein E. Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1997;13:1395-402.
215. Amado RG, Mitsuyasu RT, Zack JA. Gene therapy for the treatment of AIDS: animal models and human clinical experience. Front Biosci 1999;4:D468-75.
216. Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus infection. Clin Diagn Virol 1998;10:163-71.
217. Temsamani J, Guinot P. Antisense oligonucleotides: a new therapeutic approach. Biotechnol Appl Biochem 1997;26:65-71.